DRUG OR TOOL, DESIGN OR SERENDIPITY

CLMJ VERLINDE*, BW DIJKSTRA

*Corresponding author for this work

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

    3 Citations (Scopus)

    Abstract

    Iterative protein structure-based ligand design has led to a 'selective' inhibitor of human nonpancreatic secretory phospholipase A(2) which provides a new tool for probing metabolic pathways and may lead to a useful drug.

    Original languageEnglish
    Pages (from-to)429-432
    Number of pages4
    JournalNature Structural Biology
    Volume2
    Issue number6
    Publication statusPublished - Jun-1995

    Keywords

    • SYNOVIAL-FLUID PHOSPHOLIPASE-A2
    • INDOMETHACIN
    • RESOLUTION

    Fingerprint

    Dive into the research topics of 'DRUG OR TOOL, DESIGN OR SERENDIPITY'. Together they form a unique fingerprint.

    Cite this